

Enzon Agrees To Sell Specialty Pharmaceutical Business To Sigma-tau Group - Quick Facts

RTTNews) - Enzon Pharmaceuticals, Inc. (ENZN: [News](#)) announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for \$300 million plus an additional amount of up to \$27 million based on success milestones. Enzon will also receive royalties of 5 to 10% on incremental net sales above a 2009 baseline amount from Enzon's four marketed specialty pharmaceutical products through 2014. The transaction is expected to be completed during the first quarter of 2010.

Enzon's specialty pharmaceutical business includes four marketed products namely Oncaspar, Adagen, DepoCyt, and Abelcet, as well as the manufacturing facility in Indianapolis, Indiana which will be purchased by a US subsidiary of Sigma-Tau Pharmaceuticals, Inc. (Maryland). Sigma-Tau Pharmaceuticals will distribute the products in the US market.